Australia markets closed

Arovella Therapeutics Limited (ALA.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1300+0.0100 (+8.33%)
At close: 04:10PM AEST
Currency in AUD

Valuation measures4

Market cap (intra-day) 136.52M
Enterprise value 133.05M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.09k
Price/book (mrq)43.57
Enterprise value/revenue 3.82k
Enterprise value/EBITDA -13.18

Trading information

Stock price history

Beta (5Y monthly) -0.64
52-week change 380.56%
S&P500 52-week change 322.38%
52-week high 30.1850
52-week low 30.0420
50-day moving average 30.1337
200-day moving average 30.1059

Share statistics

Avg vol (3-month) 32.34M
Avg vol (10-day) 31.18M
Shares outstanding 51.05B
Implied shares outstanding 61.05B
Float 8735.02M
% held by insiders 120.78%
% held by institutions 18.21%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 314 Nov 2019

Financial highlights

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-207.00%

Management effectiveness

Return on assets (ttm)-98.07%
Return on equity (ttm)-276.74%

Income statement

Revenue (ttm)1.97M
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)36.10%
Gross profit (ttm)N/A
EBITDA -9.38M
Net income avi to common (ttm)-10.23M
Diluted EPS (ttm)-0.0100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.76M
Total cash per share (mrq)0
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.37
Book value per share (mrq)0.00

Cash flow statement

Operating cash flow (ttm)-6.41M
Levered free cash flow (ttm)-3.69M